Wednesday, 18 Oct 2017

You are here

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com: 

  1. FDA accepts Pfizers NDA for Xeljanz (tofacitinib) as treatment for moderately to severely active ulcerative colitis https://t.co/QJi2g2Bfao
  2. FDA rejects Romosuzumab (anti-Sclerostin OP Rx) w/ a complete response letter asking for resubmission, more data https://t.co/Xz8DjEMtUM
  3. RA ACPA+ have higher economic burden with MORE early DMARD use (71 vs 50%) & Biologic use (20 vs 12%); more MD visits; & more Total costs https://t.co/le0vgHKaPL
  4. Mucosal immunity seen in at-risk RA (preclinical) people who had more IgA producing plasmablasts (39%) than established RA or normal controls(1%, 9%) https://t.co/Bi9F2inrtb 
  5. 7 patients with Active Refractory Takayasu arteritis treated with RTX showed mixed results - 3 achieved remission but 4 failed to respond to RTX. https://t.co/rXSNc6qpTn  
  6. Study of 38,924 shows dairy intake assoc with an increased risk of OA hip replacement (unrelated to age, BMI, smoking, activity https://t.co/T37NXzn40B
  7. 1979-2013 Septic arthritis in RA has increased and associated with more biologic use, polyarticular infections, MRSA (6% v 31%); but same outcomes https://t.co/2JNqp5n1GJ
  8. Alcohol & Smoking assoc w/ 2 fold risk of Hand OA. but being overweight or obese is NOT. https://t.co/pAa2uiLa9B
  9. MTX has yet to be shown to benefit Osteoarthritis; but there is a new PROMOTE trial looking at pain reduction. Still enrolling. https://t.co/yc3qSEPujJ
  10. Zurampic 200mg + Uloric fails vs Uloric alone at achieving two primary endpoints SUA<5 (57% vs 47%) & topus resolution (no diff btw groups). https://t.co/LtjJyKIQ28
  11. Adverse Maternal and Fetal Outcomes in Lupus - and Pre-Lupus Too 
  12. Acute Coronary Syndrome Increased in Early Rheumatoid Arthritis 
  13. Long-Term Additive Cardiovascular Benefit of Plaquenil and Aspirin in Lupus 
  14. FDA Approves Tremfya (guselkumab) for Plaque Psoriasis

 


Rheumatologists' Comments

Decades ago waited 12 weeks to diagnose RA. Now can think pre RA Great! Anticipating more in shorter time frame.

More Like This

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.

29 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.